Comparison of injection-site reactions between the etanercept biosimilar SB4 and the reference etanercept in patients with rheumatoid arthritis from a phase III study

Br J Dermatol. 2018 Mar;178(3):e215-e216. doi: 10.1111/bjd.16032. Epub 2018 Jan 30.

Authors

G Girolomoni¹, S R Feldman², P Emery³, J Ghil⁴, J W Keum⁴, S Y Cheong⁴, E Hong⁴

Affiliations

¹ Section of Dermatology and Venereology, Department of Medicine, University of Verona, Piazzale A Stefani 1, 37126 Verona, Italy.
² Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, NC 27101, U.S.A.
³ Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, U.K.
⁴ Samsung Bioepis Co., Ltd, Incheon, Republic of Korea.

PMID: 29023641
DOI: 10.1111/bjd.16032

No abstract available

Publication types

Clinical Trial, Phase III
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antirheumatic Agents / administration & dosage*
Antirheumatic Agents / adverse effects*
Arthritis, Rheumatoid / drug therapy*
Biosimilar Pharmaceuticals / administration & dosage
Biosimilar Pharmaceuticals / adverse effects*
Drug Eruptions / etiology*
Etanercept / administration & dosage
Etanercept / adverse effects*
Humans
Injections, Intradermal / adverse effects
Time Factors

Substances

Antirheumatic Agents
Biosimilar Pharmaceuticals
Etanercept

Grants and funding